Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on Krystal Biotech. The associated price target remains the same with $202.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ritu Baral has given her Buy rating due to a combination of factors including Krystal Biotech’s recent financial performance and strategic initiatives. The company reported Vyjuvek revenues of $96 million, which surpassed both the consensus and buy-side expectations. This was attributed to patient restarts after drug holidays and the initial impact of expanding the sales force.
Additionally, Krystal Biotech is poised for further growth with the upcoming European launch of Vyjuvek in Germany and France, as well as a planned Japanese launch. The company maintains a strong cash position of $821 million and has provided guidance that suggests a return to revenue growth in the fourth quarter, driven by patient restarts and increased sales efforts. These factors collectively support the Buy rating, indicating confidence in the company’s future performance.
According to TipRanks, Baral is a 5-star analyst with an average return of 12.0% and a 48.80% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Krystal Biotech, and Neurogene.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $240.00 price target.